300858.SHE Beijing Scitop Bio Tech Co Ltd
- Market cap
- CNY 3.47B
- P/E
- 62.8x
- P/B
- 1.94x
- ROE
- 2.7%
- Dividend yield
- 1.14%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300858.SHE undervalued?
Graham number300858.SHE trades 132.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Scitop Bio Tech Co Ltd fundamental analysis
No fundamental analysis for Beijing Scitop Bio Tech Co Ltd yet.
Beijing Scitop Bio Tech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Scitop Bio Tech Co Ltd
Beijing Scitop Bio-tech Co., Ltd. engages in the research, development, production, and sale of probiotic, postbiotics, and microecological preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmi…
Full company profileBeijing Scitop Bio Tech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Scitop Bio Tech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 261M | 284M | 318M | 308M | 339M | 365M | 369M | 299M | 303M | 366M | 356M |
| Gross Profit | 116M | 133M | 157M | 157M | 164M | 183M | 192M | 163M | 176M | 188M | 158M |
| Operating Income | 20.1M | 87.8M | 107M | 111M | 118M | 125M | 128M | 103M | 109M | 84.4M | 34.9M |
| EBITDA | 26.1M | 91.8M | 111M | 116M | 123M | 140M | 143M | 121M | 134M | 138M | 51.5M |
| Net Income | 11.5M | 71.3M | 91.9M | 93.3M | 96.6M | 110M | 110M | 93.5M | 94.4M | 94.5M | 47.7M |
| EPS | 0.10 | 0.44 | 0.55 | 0.56 | 0.51 | 0.49 | 0.49 | 0.35 | 0.36 | 0.36 | 0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 266M | 337M | 374M | 466M | 999M | 1.04B | 1.79B | 1.81B | 1.92B | 2.02B | 1.97B |
| Total Liabilities | 71.7M | 56.3M | 71.9M | 66.1M | 66.7M | 73.3M | 94.0M | 77.1M | 126M | 176M | 212M |
| Shareholders' Equity | 193M | 281M | 302M | 400M | 933M | 967M | 1.70B | 1.73B | 1.79B | 1.84B | 1.76B |
| Cash & Short-term Investments | 30.8M | 122M | 55.1M | 100M | 371M | 573M | 1.16B | 827M | 405M | 99.7M | 155M |
| Total Debt | 13.0M | - | 8.30M | - | 8.34M | 8.61M | 7.70M | 9.90M | 3.23M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 32.7M | 84.0M | 89.6M | 98.3M | 66.7M | 110M | 148M | 107M | 142M | 123M | - |
| Capital Expenditure | 21.1M | 47.2M | 96.0M | 46.2M | 21.3M | 67.6M | 84.2M | 178M | 211M | 296M | 79.5M |
| Free Cash Flow | 11.7M | 36.8M | -6.44M | 52.0M | 45.4M | 42.7M | 64.3M | -71.2M | -69.4M | -173M | -37.3M |
| Ratios | |||||||||||
| ROE | 6.0% | 25.4% | 30.5% | 23.3% | 10.4% | 11.3% | 6.5% | 5.4% | 5.3% | 5.1% | 2.7% |
| ROA | 4.3% | 21.1% | 24.6% | 20.0% | 9.7% | 10.5% | 6.1% | 5.2% | 4.9% | 4.7% | 2.4% |
| Net Profit Margin | 4.4% | 25.1% | 28.9% | 30.3% | 28.5% | 30.0% | 29.8% | 31.2% | 31.2% | 25.8% | 13.4% |
| Debt to Equity | 0.07x | - | 0.03x | - | 0.01x | 0.01x | 0.00x | 0.01x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Scitop Bio Tech Co Ltd dividends
- Dividend yield
- 1.14%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 41.8%
- Ex-dividend date
- Jul 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 39.5M | 0.15 | 41.8% |
| 2024 | CNY 39.5M | 0.15 | 41.9% |
| 2023 | CNY 52.7M | 0.20 | 56.4% |
| 2022 | CNY 74.5M | 0.33 | 67.8% |
| 2021 | CNY 82.5M | 0.37 | 75.3% |
| 2020 | CNY 82.5M | 0.43 | 85.4% |
| 2019 | CNY 356K | 0.00 | 0.4% |
| 2018 | CNY 69.6M | 0.42 | 75.8% |
| 2017 | CNY 20.4M | 0.13 | 28.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jun 30, 2023.
Who owns Beijing Scitop Bio Tech Co Ltd
- Insiders 47.96%
- Institutions 2.87%
- Public & others 49.17%
- Shares outstanding 263M
- Free float 143M
Beijing Scitop Bio Tech Co Ltd company profile
- Company name
- Beijing Scitop Bio Tech Co Ltd
- Ticker
- 300858.SHE
- ISIN
- CNE100004181
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 413
- Fiscal year end
- December
- Address
- No. 1-2, No. 31, Niuhe Road, Beijing, China, 101407
- Phone
- 86 40 0650 6833
- Website
- scitop.cn
About Beijing Scitop Bio Tech Co Ltd
Beijing Scitop Bio-tech Co., Ltd. engages in the research, development, production, and sale of probiotic, postbiotics, and microecological preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmission, as well as exercise, bone, heart, and skin health applications. The company also offers microecological preparations and related application technologies for ruminants, monogastric livestock and poultry animals, aquatic animals, and pets. In addition, it develops and promotes microbial agents, such as microbial fertilizers, bio-organic fertilizers, organic material decomposition agents, etc. for vegetable, fruit, edible fungus, forage grass, and crop planting. Beijing Scitop Bio-tech Co., Ltd. was founded in 2003 and is headquartered in Beijing, China.
Beijing Scitop Bio Tech Co Ltd management
7- Mr. Xiaojun LiuGM & Director · born 1981
- Mr. Ziying YuAccounting Supervisor, Deputy GM & CFO · born 1964
- Mr. Xiangqian QiaoDeputy GM & Director · born 1974
- Mr. Weichen BaoDeputy General Manager · born 1984
- Mr. Lingyu ZhangBoard Secretary & Deputy GM · born 1990
- Mr. Jianjun ZhangDeputy General Manager · born 1983
- Ms. Qimuge SuduDeputy General Manager · born 1983